Celldex Therapeutics (CLDX) Other Operating Expenses (2010 - 2023)

Celldex Therapeutics' Other Operating Expenses history runs 14 years deep, the most recent figure standing at $12.5 million for Q4 2023.

• In Q4 2023, Other Operating Expenses changed N/A year-over-year to $12.5 million; the TTM figure through Sep 2024 stood at $12.5 million (changed N/A YoY), while the FY2023 annual figure was -$12.5 million, down 282.16% from the prior year.
• Other Operating Expenses was $12.5 million for Q4 2023 at Celldex Therapeutics, up from $6.3 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $12.5 million in Q4 2023 to a low of -$1.5 million in Q1 2019.
• Historically, Other Operating Expenses has averaged $1.7 million across 5 years, with a median of $205000.0 in 2021.
• The sharpest annual moves came in 2020 and 2022: Other Operating Expenses sank 131.32% in 2020, then jumped 2200.0% in 2022.
• A 5-year view of Other Operating Expenses shows it stood at -$318000.0 in 2019, then surged by 105.66% to $18000.0 in 2020, then surged by 1038.89% to $205000.0 in 2021, then jumped by 2973.17% to $6.3 million in 2022, then jumped by 98.41% to $12.5 million in 2023.
• The last three Other Operating Expenses figures came in at $12.5 million (Q4 2023), $6.3 million (Q2 2022), and $536000.0 (Q1 2022), per Business Quant data.